Background: With the rapid development of artificial intelligence (AI) technologies, AI chatbots have been widely applied in the healthcare to provide patients with immediate information. Many people feel embarrassed to discuss gynecomastia in person and turn to online resources for support. Objective: This study aims to fill this gap by evaluating the performance of five popular AI chatbots (ChatGPT, DeepSeek, Gemini, Perplexity, and Copilot) in answering questions about gynecomastia, focusing on their reliability, quality, readability, and guideline consistency. Methods: In this study, the top 25 gynecomastia-related queries searched globally from 2004 to 2025 were retrieved from Google Trends and input into five AI chatbots for responses. The reliability and quality of responses were assessed using the DISCERN questionnaire and the Ensuring Quality Information for Patients (EQIP) tool. Readability was analyzed via the Flesch-Kincaid Grade Level (FKGL) and Flesch-Kincaid Reading Ease Score (FKRE). Accuracy, supplementary, and incompleteness were compared with the European Association of Andrology guidelines. Results: Copilot had the lowest DISCERN score (median [interquartile range (IQR)]: 41.5[36.0-45.0]), while DeepSeek performed best in EQIP scoring (median [IQR]: 60.4[59.0-64.1]). For readability, ChatGPT exhibited the highest FKGL score (mean ± standard deviation (SD): 15.1 ± 2.0) but the lowest FKRE score (mean ± SD: 15.1 ± 2.0), indicating the poorest readability. In contrast, DeepSeek achieved the lowest FKGL (mean ± SD: 11.0 ± 1.2), suggesting superior readability. Guideline consistency analysis revealed an overall accuracy of 85.71% for AI responses, but key details were often omitted. Conclusion: AI chatbots provide immediate informational support for gynecomastia patients, but there is significant variability in readability and reliability, alongside risks of omitting guideline content.
13 November 2025 in World Journal of Surgical Oncology
Vacuum-assisted breast biopsy (VABB) is a widely adopted minimally invasive technique for the diagnosis and treatment of breast lesions. However, the procedure heavily relies on real-time ultrasound guidance, posing significant challenges for junior surgeon who lack radiological experience in accurately localizing both the lesion and the biopsy needle. Currently, there is no dedicated real-time artificital intelligence (AI) navigation system specifically designed for VABB procedures. We developed a novel two-stage real-time AI navigation system based on the YOLOv11 deep learning architecture. Model 1 performs initial localization of the tumor and the cutter slot, while Model 2 focuses on real-time tracking of the knife and tumor during resection. The system was trained and validated using 22,278 annotated ultrasound images from 167 VABB procedures conducted at People's Hospital of China Medical University. A rigorous three-fold cross-validation was implemented to assess model performance, and the localization accuracy was compared with that of junior surgeon. Additionally, we evaluated the system’s real-time processing performance on both GPU and CPU platforms. The AI system demonstrated superior performance across all evaluated metrics. ForModel 1, the mean Average Precision at IoU threshold 0.5 (mAP50) for tumor detection and groove localization reached 0.907 and 0.671, respectively, significantly outperforming junior surgeon (0.551 and 0.120). For Model 2, the mAP50 for tumor and needle tip tracking were 0.829 and 0.765, respectively, compared to 0.758 and 0.350 achieved by surgeons. The system achieved a real-time processing speed of 1.2 ms per frame on GPU and 32.6 ms per frame on CPU. This study presents the first dedicated AI-based navigation system for VABB, showing substantial improvement in localization accuracy over manual operation by junior surgeon. The system’s robust detection capability and real-time performance highlight its strong potential for clinical application, especially in surgical training and complex cases requiring precise instrument control. Clinical Trial Registration No. 2022JH2/101300026